BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16846069)

  • 1. [Inhibition of the process of Glu-plasminogen activation by tissue activator with fibrin, DDE-complex, and D-dimer using alpha-2-antiplasmin].
    Hrynenko TV; Zadorozhna MB; Platonova TM; Volkov HL
    Ukr Biokhim Zh (1999); 2005; 77(5):45-51. PubMed ID: 16846069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Binding of alpha-2-antiplasmin with fibrinogen/fibrin and their fragments independent of factor XIII].
    Zadorozhna MB; Hrynenko TV; Iusova OI; Volkov HL
    Ukr Biokhim Zh (1999); 2004; 76(5):71-7. PubMed ID: 16100900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulation with alpha-2-antiplasmin of Glu-plasminogen activation by tissue activator on fibrin].
    Hrynenko TV; Zadorozhna MB; Iusova OI
    Ukr Biokhim Zh (1999); 2006; 78(3):106-12. PubMed ID: 17100317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fibrin degradation products on fibrinolytic process.
    Yatsenko TA; Rybachuk VM; Yusova OI; Kharchenko SM; Grinenko TV
    Ukr Biochem J; 2016; 88(2):16-24. PubMed ID: 29227597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
    Rouy D; Anglés-Cano E
    Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fibrin and alpha2-antiplasmin on plasminogen activation by staphylokinase.
    Okada K; Ueshima S; Takaishi T; Yuasa H; Fukao H; Matsuo O
    Am J Hematol; 1996 Nov; 53(3):151-7. PubMed ID: 8895684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen fragments K 1-3 and K 5 bind to different sites in fibrin fragment DD.
    Grinenko TV; Kapustianenko LG; Yatsenko TA; Yusova OI; Rybachuk VN
    Ukr Biochem J; 2016; 88(3):36-45. PubMed ID: 29235323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites.
    Yakovlev S; Makogonenko E; Kurochkina N; Nieuwenhuizen W; Ingham K; Medved L
    Biochemistry; 2000 Dec; 39(51):15730-41. PubMed ID: 11123898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN; Jackson KW; McKee PA
    Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.
    Edelberg JM; Pizzo SV
    Biochem J; 1992 Aug; 286 ( Pt 1)(Pt 1):79-84. PubMed ID: 1381585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha Domain deletion converts streptokinase into a fibrin-dependent plasminogen activator through mechanisms akin to staphylokinase and tissue plasminogen activator.
    Sazonova IY; Robinson BR; Gladysheva IP; Castellino FJ; Reed GL
    J Biol Chem; 2004 Jun; 279(24):24994-5001. PubMed ID: 15069059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
    Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
    J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin.
    Angles-Cano E; Rouy D; Lijnen HR
    Biochim Biophys Acta; 1992 Dec; 1156(1):34-42. PubMed ID: 1472536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator.
    Silva MM; Thelwell C; Williams SC; Longstaff C
    J Thromb Haemost; 2012 Nov; 10(11):2354-60. PubMed ID: 22974122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.